High Ki-67 expression is a poor prognostic indicator of 5-year survival in patients with invasive breast cancer

Asian Pacific Journal of Cancer Prevention

Volumn 12, Issue 11, 2011, Pages 3101-3104

  Yang, Xue Qin ^a,b   Wang, Fu Bing ^a   Chen, Chuang ^a   Peng, Chun Wei ^a   Zhang, Jing Fang ^b   Li, Yan ^a  

^a ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b JINGCHU UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

Breast cancer; Ki 67; Prognosis; Recurrence free survival

Indexed keywords

EID: 84863300044     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Ayoub N, Lucas C, Kaddoumi A (2011). Genomics and pharmacogenomics of breast cancer: current knowledge and trends. Asian Pac J Cancer Prev, 12, 1127-40.
2. Chen C, Peng J, Xia H, et al(2010). Quantum-dot-based immunofluorescent imaging of HER2 and ER provides new insights into breast cancer heterogeneity. Nanotechnology, 21, 095101.
3. Chen C, Peng J, Xia HS, et al(2009). Quantum dots-based immunofluorescence technology for the quantitative determination of HER2 expression in breast cancer. Biomaterials, 30, 2912-8.
4. Colozza M, Sidoni A, Piccart-Gebhart M (2010). Value of Ki67 in breast cancer: the debate is still open. Lancet Oncol, 11, 414-5.
5. De Azambuja E, Cardoso F, De Castro Jr G et al(2007). Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer, 96, 1504-13.
6. Gerdes J, Lemke H, Baisch H, et al(1984). Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol, 133, 1710-5.
7. Gerdes J, Li L, Schlueter C, et al(1991). Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol, 138, 867-73.
8. Gerdes J, Schwab U, Lemke H, Stein H (1983). Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer, 31, 13-20.
9. Goldhirsch A, Ingle JN, Gelber RD, al(2009). Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol, 20, 1319-29.
10. González-Vela MC, Garijo MF, Fernández F, Val-Bernal JF (2001). MIB1 proliferation index in breast infiltrating carcinoma: comparison with other proliferative markers and association with new biological prognostic factors. Histol Histopathol, 16, 399-406.
11. American Society of Clinical Oncology: American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer
12. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
13. Jonat W, Arnold N (2011). Is the Ki-67 labelling index ready for clinical use? Ann Oncol, 22, 500-5002.
14. Karanikas G, Koronakis N, Lagoudianakis EE, et al(2011). The value of proliferation indexes in breast cancer. Eur J Gynaecol Oncol, 31, 181-4.
15. Pavelic ZP, Pavelic L, Lower EE, Gapany M, Gapany S, et al(1992). c-myc, c-erbB-2, and Ki-67 expression in normal breast tissue and in invasive and noninvasive breast carcinoma. Cancer Res, 52, 2597-602.
16. Santisteban M, Reynolds C, Barr Fritcher EG, et al(2010). Ki67: a time-varying biomarker of risk of breast cancer in atypical hyperplasia. Breast Cancer Res Treat, 121, 431-7.
17. Stuart-Harris R, Caldas C, Pinder SE, Pharoah P (2009). Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst, 101, 736-50.
18. Viale G, Giobbie-Hurder A, Regan MM, et al(2008). Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol, 26, 5569-75.
19. Viale G, Regan MM, Mastropasqua MG, et al(2008). Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Natl Cancer Inst, 100, 207-12.
20. Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA (2010). Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol, 11, 174-83.